17,248 Shares in Balchem Co. (NASDAQ:BCPC) Bought by Edgestream Partners L.P.

Edgestream Partners L.P. bought a new position in Balchem Co. (NASDAQ:BCPC) during the second quarter, according to its most recent filing with the SEC. The firm bought 17,248 shares of the basic materials company’s stock, valued at approximately $2,655,000. Edgestream Partners L.P. owned approximately 0.05% of Balchem as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Principal Securities Inc. bought a new stake in shares of Balchem in the 4th quarter worth approximately $28,000. Bessemer Group Inc. raised its holdings in shares of Balchem by 568.9% in the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after acquiring an additional 256 shares in the last quarter. YHB Investment Advisors Inc. bought a new position in shares of Balchem in the 1st quarter worth $69,000. GAMMA Investing LLC lifted its stake in Balchem by 18.0% during the first quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock worth $73,000 after purchasing an additional 72 shares during the last quarter. Finally, TD Asset Management Inc bought a new stake in Balchem in the 2nd quarter worth approximately $200,000. Institutional investors and hedge funds own 87.91% of the company’s stock.

Balchem Stock Performance

Balchem stock opened at $176.04 on Thursday. The company has a market capitalization of $5.71 billion, a P/E ratio of 49.73, a PEG ratio of 5.18 and a beta of 0.65. The stock’s 50 day moving average is $171.03 and its 200 day moving average is $159.00. Balchem Co. has a twelve month low of $110.74 and a twelve month high of $186.03. The company has a quick ratio of 1.79, a current ratio of 2.83 and a debt-to-equity ratio of 0.26.

Balchem (NASDAQ:BCPC) last posted its earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. Balchem had a net margin of 12.52% and a return on equity of 10.94%. The business had revenue of $234.08 million for the quarter, compared to analysts’ expectations of $241.26 million. On average, equities research analysts predict that Balchem Co. will post 3.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Balchem

In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the completion of the sale, the senior vice president now directly owns 8,540 shares of the company’s stock, valued at $1,537,627. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.25% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. StockNews.com downgraded Balchem from a “buy” rating to a “hold” rating in a report on Monday, July 29th. HC Wainwright boosted their price target on shares of Balchem from $170.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.